A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Ringkasan berita
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Ikuti berita terkini daripada penerbit yang dipercayai dengan ringkasan ringkas. Buka pautan sumber asal untuk butiran.